BJClub La Storia
BJClub La Storia
Adjuvant anastrozole versus exemestane versus letrozole
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 – In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
2017 – Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
2017 – Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
2015 – Measures of Outcome inMetastatic Breast Cancer: Insights From a Real-World Scenario
2015 – Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole- Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer
2015 – Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
2014 – Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
2013 – Comprehensive molecular portraits of human breast tumours
2012 – Everolimus in Postmenopausal Hormone- Receptor–Positive Advanced Breast Cancer
2011 – Current and emerging biomarkers in breast cancer: prognosis and prediction
2009 – Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 – Biological Processes Associated with Breast Cancer Clinical Outcome Depend on theMolecular Subtypes
L’importanza della ricerca in oncologia.
Evento Digitale Online.
Progetto realizzato da:
Con il contributo non condizionante di
2018 © Copyright Breast Journal Club -
Web Agency Monza
- by Veralto.it